India's First Dengue Vaccine Clinical Trial Reaches 70% Enrollment

India is making significant strides in the fight against dengue with its first vaccine, DengiAll, currently in Phase III clinical trials. Union Minister Prataprao Jadhav announced that 70% of the required participants have been enrolled, with the trial expected to conclude by October. This indigenous vaccine, developed by Panacea Biotec, targets all four dengue virus subtypes and has shown promising results in earlier studies. With over 573,000 confirmed dengue cases reported in 2024, the need for effective prevention measures is critical. The government is also implementing national guidelines for dengue treatment, emphasizing hospital preparedness. Stay tuned for more updates on this groundbreaking development.

By Narendra Chaudhary Aug 1, 2025, 16:38 IST

Progress on Dengue Vaccine Development

New Delhi, Aug 1: The Phase III clinical trial for India's inaugural dengue vaccine has successfully enrolled 70% of its participants, as reported by Union Minister of State for Health, Prataprao Jadhav, during a parliamentary session on Friday.

In a written statement to the Lok Sabha, Jadhav provided insights into the Phase III clinical trial of the indigenous dengue vaccine, DengiAll.

“The trial is set to include over 10,000 participants, with more than 70% already enrolled,” Jadhav stated, adding that the trial is expected to conclude by October.

“This trial is being conducted at 20 locations throughout India, with an estimated budget of Rs 1.3 to 1.5 crore allocated for each site,” he further explained.

DengiAll, a tetravalent dengue vaccine, is being developed by Panacea Biotec under a licensing agreement with the National Institutes of Health (NIH). This vaccine aims to combat all four subtypes of the dengue virus and has demonstrated encouraging results in previous trials.

According to the National Centre for Disease Control (NCDC), there were 573,563 confirmed dengue cases reported in 2024.

“The Indian Council of Medical Research (ICMR) indicates that all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4) are prevalent and co-circulate in India,” Jadhav noted.

It is possible for multiple serotypes to exist in the same area and even infect an individual simultaneously.

“Therefore, participants in the ICMR vaccine trial have been recruited from various regions where these four serotypes are active, to evaluate the vaccine's effectiveness against all of them,” he added.

DengiAll is being developed by Panacea Biotec in collaboration with the NIH, the leading US federal agency for biomedical research. Initial findings indicate no safety issues associated with this one-shot vaccine aimed at combating the mosquito-borne viral disease.

Jadhav highlighted that, according to ICMR, there are currently no specific antiviral treatments or licensed vaccines available for dengue.

The government has also established national guidelines for the treatment and management of dengue cases, focusing on hospital preparedness for effective case management, the minister concluded.